Following treatment with two standard courses of chemotherapy, complete remission was observed in 40% of the AML patients who had high TβRII expression, which was a significantly smaller fraction than the fraction of patients with low TβRII expression who achieved remission (69.2%) (Table 1). Here, TGFBR2 is linked to acute myeloid leukemia.